---
title: "Sihuan Pharmaceutical’s Medical Aesthetics Push Lifts 2025 Revenue and Margins"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281120761.md"
description: "Sihuan Pharmaceutical Holdings Group (HK:0460) reported a significant rebound in 2025, with revenue rising 37.7% to RMB2.62 billion and gross profit increasing 45.1% to RMB1.80 billion, resulting in a gross margin of 68.8%. The medical aesthetics segment became the largest business, nearly doubling its revenue to RMB1.49 billion. Despite a 13% decline in the generic drug segment, the company is strategically pivoting towards high-growth aesthetics and innovative therapies. The current analyst rating for the stock is a Hold with a price target of HK$1.50."
datetime: "2026-03-31T04:14:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281120761.md)
  - [en](https://longbridge.com/en/news/281120761.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281120761.md)
---

# Sihuan Pharmaceutical’s Medical Aesthetics Push Lifts 2025 Revenue and Margins

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An announcement from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.

Sihuan Pharmaceutical reported a sharp rebound in 2025, with total revenue rising 37.7% year on year to RMB2.62 billion and group gross profit climbing 45.1% to RMB1.80 billion, lifting gross margin to 68.8%. The performance marks a shift in the company’s revenue mix, as higher-margin medical aesthetics became its largest business, exceeding half of total sales for the first time.

The medical aesthetics segment nearly doubled revenue to RMB1.49 billion, driven by strong uptake of core product Letybo, broader channel coverage to more than 8,000 institutions, and rapid growth from newly approved PLLA and PCL fillers and a niche facial revitalizer. Innovative and other medicines more than tripled sales on the back of diabetes products and initial commercialization at Xuanzhu Biopharm, while the generic drug segment declined 13%, with cost controls helping offset profit pressure and reinforcing the strategic pivot toward premium, high-growth aesthetics and innovative therapies.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

**More about Sihuan Pharmaceutical Holdings Group**

Sihuan Pharmaceutical Holdings Group is a Bermuda-incorporated pharmaceutical company listed in Hong Kong, operating across medical aesthetics, innovative drugs and generic medicines. Its portfolio includes flagship medical aesthetics brands such as botulinum toxin product Letybo and newly launched regenerative fillers, alongside diabetes-related therapies and other specialty pharmaceuticals aimed at the China healthcare market.

**Average Trading Volume:** 33,215,199

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$12.69B

For a thorough assessment of 0460 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [00460.HK](https://longbridge.com/en/quote/00460.HK.md)

## Related News & Research

- [Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy | AVAI Stock News](https://longbridge.com/en/news/287067719.md)
- [Gen Z drives demand for wellness and appearance-linked therapies](https://longbridge.com/en/news/287079525.md)
- [CureDuchenne Announces Partnership with Tevard Biosciences to Advance Suppressor tRNA Therapy for the Treatment of Duchenne Muscular Dystrophy](https://longbridge.com/en/news/287098032.md)
- [KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy](https://longbridge.com/en/news/287059695.md)
- [06:50 ETBliss Launches Bliss Pro™, an Accessible Pro-Grade Skincare Line of Next-Gen Ingredients and Treatments](https://longbridge.com/en/news/286898081.md)